Interviews

Rathore Discusses Study on Biosimilar Application Failures

July 22nd 2020

The Center for Biosimilars® interviewed Anurag S. Rathore, PhD, whose team of investigators evaluated why applications for biosimilar approvals do not succeed. Large companies as well as small find the approval process challenging, but there is a learning curve that may be followed by more consistent approvals, he explains.

Part 1: Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman

July 21st 2020

Video

Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn Veltrop and Harkrider LLP, met with The Center for Biosimilars® to discuss how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act, as well as the new challenges follow-on manufacturers will face.

Part 2: Celltrion Marketing Head Discusses Company's Future

July 16th 2020

Video

Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses Celltrion’s biosimilar pipeline, the competitive landscape for its products, and its plans to build a biosimilar production center in Wuhan, China.

Celltrion: Infliximab Biosimilar Shows Promise for COVID-19

July 14th 2020

Video

Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses how Celltrion's infliximab biosimilar can aid in the treatment of coronavirus disease 2019 (COVID-19)–related inflammation, as well as the company’s launch plans for biosimilars through 2030.

Kathy Oubre: Other Players Complicate Biosimilar Use for Cancer Centers

July 2nd 2020

Video

Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association and member of the board of directors for the Community Oncology Alliance, discusses how payers, pharmacy benefit managers, and manufacturers make providing biosimilars complicated for patients and providers.

Ryan Haumschild, PharmD, Outlines Ways to Boost Physician Confidence in Biosimilars

July 1st 2020

Video

Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, discussed results to the survey he conducted on biosimilar utilization and planned initiatives about how to increase physician confidence in biosimilars.

Part 2: Nick Mitrokostas on the Race for the First Interchangeable Biosimilar

June 24th 2020

Video

Nick Mitrokostas, an intellectual property law attorney with Goodwin Proctor in Boston and editor-in-chief of Big Molecule Watch, discussed the building anticipation for the first interchangeable biosimilar and whether the FDA is doing enough to facilitate the development of more biosimilars and quell anticompetitive practices.

Part 1: Nick Mitrokostas on How COVID-19, FDA Rule Changes Are Shaping the Biosimilar Market

June 23rd 2020

Video

Nick Mitrokostas, an intellectual property law attorney with Goodwin Proctor in Boston and editor in chief of Big Molecule Watch, discussed the impact on the US biosimilar market from the coronavirus disease 2019 (COVID-19) pandemic and the recent change to the Biologics Price Competition and Innovation Act (BPCIA).

Part 2: Christine Simmon Discusses Payer Influence on Provider Behavior

June 18th 2020

Video

Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discussed the new pathway for insulin biosimilars and the struggles between payers and providers over biosimilar choice.

Part 1: Christine Simmon Discusses the Individual Mandate and Biosimilars

June 16th 2020

Video

Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discusses potential legislation that the AAM is advocating for and how the upcoming election and Supreme Court decision will affect biosimilars.